{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:09:02Z","timestamp":1778497742475,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Adelphi Real World"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Treatment guidance and real-world data assessing the management and burden of isolated proctitis (IP) are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We aimed to understand disease burden in ulcerative colitis (UC) patients with different degrees of disease extension, focusing on IP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A cross-sectional survey, with retrospective data collection, of physicians and their consulting patients was conducted in France, Germany, Italy, Spain, the United Kingdom, and the United States between January 2020 and March 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were drawn from the Adelphi Real World UC Disease Specific Programme\u2122. Physicians reported clinical presentation and treatment history for patients with UC. Patients were stratified according to their disease extension into IP (non-refractory (never received an immunomodulator (IM)\/advanced therapy (AT)) or refractory (received an IM\/AT)) and more extensive UC (MEUC) groups. Analyses were descriptive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among patients with IP (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009221) and MEUC (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091607), respectively, the most common symptoms were abdominal pain (33.8% and 26.0%), bowel urgency (22.7% and 23.6%), and fatigue (22.7% and 23.8%). Physicians also commonly reported passing mucus (19.0%), tenesmus (15.7%), and rectal bleeding (15.3%) among patients with IP. Following diagnosis, 21.3% of IP and 42.8% of MEUC patients had received an IM, and 33.5% of IP and 68.9% of MEUC patients had received an AT. According to derived total Mayo scores, at consultation, 40.3% (95% confidence interval: 33.7, 47.1) of IP and 50.4% (47.9, 52.9) of MEUC patients were in remission; the lowest proportion of patients in remission was among refractory IP patients (35.0% (25.8, 45.0)).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patients with IP experienced a range of symptoms, with many requiring treatment beyond the guideline-recommended first-line conventional therapies. In addition, the majority of IP patients with IM and\/or AT experience were not in remission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848261448080","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:12:15Z","timestamp":1778238735000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-0118","authenticated-orcid":false,"given":"Alessandro","family":"Armuzzi","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-1477","authenticated-orcid":false,"given":"Manuel","family":"Barreiro-de Acosta","sequence":"additional","affiliation":[{"name":"IBD Unit, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hur","sequence":"additional","affiliation":[{"name":"HTA, Value and Evidence, Pfizer Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Bartolome","sequence":"additional","affiliation":[{"name":"HTA, Value and Evidence, Pfizer Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Wosik","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Gastroenterology, Inflammation and Immunology, Pfizer Canada Inc., Kirkland, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Knight","sequence":"additional","affiliation":[{"name":"Autoimmune Franchise, Adelphi Real World, Bollington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanda","family":"Palace","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, Cheshire SK10 5JB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Universit\u00e9 de Lorraine, Vand\u0153uvre-l\u00e8s-Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00966-2"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx008"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/269076"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324108"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e318281327f"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2369189"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx009"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14063"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2018.1524026"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.06.016"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2013.867360"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.00033"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae038"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00061-2"},{"key":"e_1_3_4_18_2","article-title":"O77 Vedolizumab is the most effective advanced therapy in ulcerative proctitis: results from the UK NIHR IBD bioresource","volume":"74","author":"Radford S","year":"2025","unstructured":"Radford S, Yan K, Sahin B, et al. O77 Vedolizumab is the most effective advanced therapy in ulcerative proctitis: results from the UK NIHR IBD bioresource. Gut 2025; 74: A51\u2013A51.","journal-title":"Gut"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2279679"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S120101"},{"key":"e_1_3_4_23_2","unstructured":"European Pharmaceutical Market Research Association (EphMRA). Code of conduct https:\/\/www.ephmra.org\/sites\/default\/files\/2022-03\/2021%2520EPHMRA%2520Code%2520of%2520Conduct%25202.11.21.pdf (2021 accessed January 2023)."},{"key":"e_1_3_4_24_2","unstructured":"US Department of Health and Human Services. Summary of the HIPAA privacy rule http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf (2003 accessed 17 August 2022)."},{"key":"e_1_3_4_25_2","unstructured":"Health Information Technology (HITECH). Health Information Technology Act https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf (2009 accessed 17 August 2022)."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"e_1_3_4_28_2","volume-title":"Stata statistical software: release 17","author":"StataCorp","year":"2021","unstructured":"StataCorp. Stata statistical software: release 17. College Station, TX: StataCorp LLC, 2021."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100071"},{"key":"e_1_3_4_30_2","article-title":"Association of bowel urgency with quality-of-life measures in patients with moderately-to-severely active ulcerative colitis: results from phase 3 LUCENT-1 (induction) and LUCENT-2 (maintenance) studies","author":"Long MD","unstructured":"Long MD, Schreiber S, Hibi T, et al. Association of bowel urgency with quality-of-life measures in patients with moderately-to-severely active ulcerative colitis: results from phase 3 LUCENT-1 (induction) and LUCENT-2 (maintenance) studies. Crohns Colitis 360 2024; 6: otae001.","journal-title":"Crohns Colitis"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000505092"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156666"},{"key":"e_1_3_4_33_2","article-title":"S36 Disease burden and treatment patterns among patients with ulcerative colitis with isolated proctitis in the USA: a real-world study","volume":"118","author":"Chiorean MV","year":"2023","unstructured":"Chiorean MV, Hur P, Smith CC, et al. S36 Disease burden and treatment patterns among patients with ulcerative colitis with isolated proctitis in the USA: a real-world study. Am Gastroenterol 2023; 118: S10.","journal-title":"Am Gastroenterol"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620941345"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18133"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy024"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32835414b2"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.1061"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261448080","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848261448080","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261448080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:17:26Z","timestamp":1778494646000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261448080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"alternative-id":["10.1177\/17562848261448080"],"URL":"https:\/\/doi.org\/10.1177\/17562848261448080","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"17562848261448080"}}